We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




French Team Identifies Antidote for Ricin Toxin

By LabMedica International staff writers
Posted on 25 May 2010
A large team of French researchers has discovered two low molecular weight compounds that block the action of ricin, a highly toxic protein often mentioned as a possible bioterror weapon.

Ricin comprises two subunits, the A-chain and the B-chain, which are linked by a disulphide bond. More...
The B-chain facilitates cell entry and intracellular transport, and it is reductively cleaved to free the A-chain, which inactivates ribosomes and shuts down protein synthesis.

A French team, headed by investigators at the Centre National de la Recherche Scientifique (Paris, France) used a cell-based assay system to screen over 16,000 compounds for the ability to block the intracellular transport of ricin toxins.

They reported in the April 16, 2010, online edition of the journal Cell that they had identified two compounds, Retro-1 and Retro-2 that were able to inhibit the retrograde transport route of ricin from the plasma membrane to the endoplasmic reticulum. Unlike other compounds that are known to block retrograde transport, Retro-1 and Retro-2 did not affect other intracellular trafficking and did not show any toxicity.

In experiments in mice, Retro-2 was shown to block the activity of ricin, if it were given prior to the toxin. It is expected that these compounds should also inhibit other toxic proteins such as the Shiga-like toxins produced by pathogens such as E. coli, Shigella, and cholera.

Related Links:

Centre National de la Recherche Scientifique



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.